Reuters logo
Celgene spondylitis drug misses main goal in late-stage study
July 9, 2014 / 11:30 AM / 3 years ago

Celgene spondylitis drug misses main goal in late-stage study

July 9 (Reuters) - Celgene Corp said its experimental drug for the treatment of a type of arthritis that affects the spine failed to meet the main goal in a late-stage study, sending its shares down 3 percent premarket.

Patients suffering from ankylosing spondylitis who were treated with the drug, Otezla, failed to show statistically significant response compared to those on a placebo, the company said.

However, an independent data monitoring committee recommended that the study should continue unchanged. (Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below